Economic evaluation of a 100% whey-based, partially hydrolysed formula in the prevention of atopic dermatitis among French children
- 6 October 2010
- journal article
- Published by Taylor & Francis in Current Medical Research and Opinion
- Vol. 26 (11) , 2607-2626
Abstract
A pharmacoeconomic analysis was performed to determine costs, consequences and cost effectiveness of a partially hydrolysed 100% whey-based infant formula, NAN HA, manufactured by Nestlé S.A, Switzerland (PHF-W) and branded under Nidal Excel HA in France, in the prevention of atopic dermatitis (AD) in 'at risk' children when compared to standard cows' milk formula (SF) in France. A decision-analytic economic model depicting AD treatment pathways, as well as resource utilisation and costs associated with the treatment of AD in healthy yet 'at risk' French newborns who cannot be exclusively breastfed was constructed for a 12-month time horizon, including an initial 6 months of intervention with formula consumption. Model inputs were based on the literature, official formularies and expert opinion. The modelled treatment pathways included a dietary management approach (formula change), a medical treatment approach and a combination thereof. The final outcome was the expected cost per avoided case of AD, yielding an incremental cost per avoided case (ICER) of AD when comparing subjects who used PHF-W versus SF. Outcomes were presented from three perspectives: the French Ministry of Health (MOH), the subjects' family and society as a whole. A secondary analysis also compared PHF-W to extensively hydrolysed formula (EHF) in prevention. The number of avoided AD cases by selecting PHF-W over SF was 13,356 cases in a birth cohort of 185,298 'at risk' infants. The base case analysis, at 65% reimbursement, yielded expected ICERs of €1343, € -624 (savings) and €719 from the MOH, family and societal perspectives, respectively. From all three perspectives, the highest cost was attributable to formula. In case of a 35% reimbursement rate for PHF-W, the ICER was €615 from the MOH perspective, while the use of PHF-W was cost neutral at 10% reimbursement. PHF-W was cost-saving against EHF (€98-€116 million savings depending on type of EHF), when this latter was used in prevention. One-way and probabilistic sensitivity analyses confirmed the robustness of the model. Under a certain range of assumptions, this analysis based on predictive modelling has established the cost effectiveness of PHF-W in the prevention of AD in infants.Keywords
This publication has 23 references indexed in Scilit:
- Meta-analysis of a partially hydrolysed 100%-whey infant formula vs. extensively hydrolysed infant formulas in the prevention of atopic dermatitisCurrent Medical Research and Opinion, 2010
- Partially Hydrolyzed 100% Whey Protein Infant Formula and Reduced Risk of Atopic Dermatitis: A Meta‐analysisJournal of Pediatric Gastroenterology and Nutrition, 2010
- Meta-analysis of the evidence for a partially hydrolyzed 100% whey formula for the prevention of allergic diseasesCurrent Medical Research and Opinion, 2009
- Practical issues on interpretation of scoring atopic dermatitis: the SCORAD index, objective SCORAD and the three-item severity scoreBritish Journal of Dermatology, 2007
- Quality of life and childhood atopic dermatitis: the misery of living with childhood eczemaInternational Journal Of Clinical Practice, 2006
- A cost-utility analysis of pimecrolimus vs. topical corticosteroids and emollients for the treatment of mild and moderate atopic eczemaBritish Journal of Dermatology, 2006
- Cost Effectiveness of Elidel in the Management of Patients with Atopic Dermatitis in CanadaJournal of Cutaneous Medicine and Surgery, 2004
- Atopic dermatitis and the atopic marchJournal of Allergy and Clinical Immunology, 2003
- Atopic dermatitis in early infancy predicts allergic airway disease at 5 yearsClinical & Experimental Allergy, 1998
- Facteurs influençant la durée de l'allaitement maternel chez 150 femmesArchives de Pédiatrie, 1998